Pharmaceutical formulations including an immune response modifier (IRM)compound having a 2-aminopyridine moiety fused to a five-membered nitrogen-containing heterocyclic ring； a preservative system including a sorbic acidpreservative selected from the group consisting of sorbic acid, estersthereof, salts thereof, and combinations thereof； an antioxidant； and anoptional chelating agent.
